Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Allscripts (MDRX – Research Report), Certara (CERT – Research Report) and Paylocity (PCTY – Research Report).
SVB Securities analyst Stephanie Davis assigned a Buy rating to Allscripts on November 3 and set a price target of $24.00. The company’s shares closed last Friday at $15.67.
According to TipRanks.com, Davis is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Allscripts with a $20.60 average price target, implying a 44.4% upside from current levels. In a report issued on November 4, Piper Sandler also initiated coverage with a Buy rating on the stock with a $17.00 price target.
SVB Securities analyst Joy Zhang CFA maintained a Buy rating on Certara on November 4. The company’s shares closed last Friday at $10.65, close to its 52-week low of $10.60.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
Currently, the analyst consensus on Certara is a Strong Buy with an average price target of $22.00.
Mizuho Securities analyst Siti Panigrahi maintained a Hold rating on Paylocity on November 4 and set a price target of $230.00. The company’s shares closed last Friday at $201.97.
According to TipRanks.com, Panigrahi is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Paylocity with a $276.11 average price target, which is a 30.2% upside from current levels. In a report issued on October 28, D.A. Davidson also downgraded the stock to Hold with a $250.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MDRX:
- Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), Bicycle Therapeutics (BCYC) and Selecta Biosciences (SELB)
- SVB Securities Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
- SVB Securities Remains a Hold on Tabula Rasa HealthCare (TRHC)
- SVB Securities Sticks to Their Buy Rating for Fate Therapeutics (FATE)
- Immunic (IMUX) Gets a Hold from SVB Securities